All News Lobe Sciences Ltd.

Equities

Market Closed - Canadian Securities Exchange Other stock markets 09:30:00 2024-04-15 am EDT			5-day change	1st Jan Change
0.015 ^CAD	0.00%		-25.00%	-40.00%

Feb. 15	Lobe Sciences Ltd. Reports Earnings Results for the Full Year Ended August 31, 2023	CI
2023	Lobe Sciences Provides Update on L-130 Clinical Program	MT

Lobe Sciences Ltd. Reports Earnings Results for the Full Year Ended August 31, 2023	Feb. 15	CI
Lobe Sciences Provides Company Review of 2023	Jan. 08	BU
Lobe Sciences Provides Update on L-130 Clinical Program	Dec. 07	MT
Lobe Sciences Provides Update on L-130 Clinical Program	Dec. 07	BU
Lobe Sciences Ltd. Provides Update on L-130 Clinical Program	Dec. 07	CI
Lobe Sciences Provides Update on L-130 Oral Psilocin Compound	Dec. 05	MT
Lobe Sciences Provides Update on L-130 Oral Psilocin Compound	Dec. 05	BU
Lobe Sciences : Corporate Presentation	23-10-10	PU
Lobe Sciences : Corporate Presentation Q3, 2023	23-10-09	PU
Lobe Sciences Appoints CFO	23-09-18	MT
Lobe Sciences Ltd. Appoints Mathew Lee as Chief Financial Officer	23-09-18	CI
Lobe Sciences Amends Terms of Altemia Share Purchase Agreement	23-09-15	MT
Lobe Sciences, Ltd. Announces Amendment to the Acquisition of Altemia™ & Company	23-09-14	BU
Lobe Sciences Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2023	23-08-01	CI
Lobe Sciences Initiates Phase 1 Clinical Trial of L-130	23-06-27	BU
Lobe Sciences Ltd. Initiates Phase 1 Clinical Trial of L-130	23-06-27	CI
Lobe Sciences Appoints Baxter Phillips III, MBA as Chief Operating Officer	23-06-07	BU
Lobe Sciences Appoints Baxter Phillips as Chief Operating Officer	23-06-07	CI
Lobe Sciences Announces Commercial Distribution Agreement With Pentec Health for US Launch of Altemia™	23-05-17	BU
Lobe Sciences Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended February 28, 2023	23-04-28	CI

No results for this search